MxD Awarded $15 Million to Boost U.S. Manufacturing’s COVID Response

CARES Act Funding will support supply chain resiliency, medical device deployment and pharmaceutical industry production.

CARES Act Funding will support supply chain resiliency, medical device deployment and pharmaceutical industry production.

MxD has been awarded $15 million in funding from the U.S. Department of Defense via the Coronavirus Aid, Relief, and Economic Security (CARES) Act to address critical public health and infrastructure needs and to support manufacturing as it mobilizes in response to COVID-19.

MxD’s three CARES Act-funded programs will focus on supply chain resiliency and transparency, rapid and secure medical device deployment, and pharmaceutical industry production optimization.

“We did not have a pandemic in mind as we built our expertise and strategy—but with our focus on supply chain and cybersecurity issues, MxD was made for this moment, ” says MxD CEO Chandra Brown. “Our programs support both immediate and long-term efforts to address critical shortages, develop capacity for response among manufacturers, and secure the industry during these unprecedented times.”

Supply Chain Risk Alert for Wearable

A key challenge across supply chains is the secure sharing of data, including performance specifications, factory operations data or business contracts. MxD will deliver a supply chain risk alert framework tool to help the Department of Defense and the U.S. manufacturing industry map existing supply chains to identify vulnerabilities, foreign dependencies and single-source suppliers; and identify alternate or indirect suppliers. It also will have the capability to analyze public data and determine future potential disruptions in supply chains. This tool will enable manufacturers to make data-informed decisions in times of crisis or urgency and minimize impact on production capabilities.

Rapid Deployment of Medical Devices

MxD is developing a digital process to proactively connect the U.S. Food and Drug Administration (FDA) to the medical industry to expedite validation for products during fabrication. This would create a standard digital pathway for material testing, approval, and validation of the process or part being produced and would enable digital plans for additive manufacturing to be shared across the industrial base.

Capacity and Mobilization Assessment

MxD will provide lessons learned, best practices and digital tools for manufacturers to accelerate use of digital technologies to scale or flex production, increase resiliency and strengthen their supply chains—all while maintaining the highest and necessary levels of cybersecurity. This builds upon work with the FDA Office of Counterterrorism and Emerging Threat. The assessment will identify the perceived and real barriers to implementing digital technologies that could increase U.S. manufacturing capacity and decrease time to market for medical diagnostics, therapies and vaccines needed for public health emergency response.

Information on MxD’s response to COVID-19 can be found here. 

Sources: Press materials received from the company and additional information gleaned from the company’s website.

Share This Article

Subscribe to our FREE magazine, FREE email newsletters or both!

Join over 90,000 engineering professionals who get fresh engineering news as soon as it is published.

About the Author

DE Editors's avatar
DE Editors

DE’s editors contribute news and new product announcements to Digital Engineering.
Press releases may be sent to them via [email protected].

Follow DE